Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Nimotuzumab Plus Adjuvant Chemotherapy vs Adjuvant Chemotherapy Alone for Resectable Pancreatic Cancer: a Propensity Score Matching Analysis

NCT06363084 is registered in ClinicalTrials.gov with Ruijin Hospital as lead sponsor.

NCT NCT06363084
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06363084 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Nimotuzumab Plus Adjuvant Chemotherapy vs Adjuvant Chemotherapy Alone for Resectable Pancreatic Cancer: a Propensity Score Matching Analysis
Lead sponsor
Ruijin Hospital
Phase
Observational
Overall status
Completed
Start date
May 1, 2016
Completion date
June 30, 2023
Enrollment
64 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

resectable pancreatic cancer